Boston Scientific invests in stent technology:
This article was originally published in Clinica
Boston Scientific has made an equity investment in Medinol of Tel Aviv, Israel, in return for a manufacturing licence and exclusive worldwide marketing rights to stents resulting from the alliance. The NIR coronary stent developed by Dr Kobi Richter, founder and chairman of privately-owned Medinol, is expected to be launched in Europe in the first half of 1996. "In combination with Boston Scientific's diverse balloon technologies, we think the NIR technology represents an important platform for a wide range of stents for many of the markets we serve," says Pete Nicholas, Boston's chairman and CEO.